Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Light Dosimetry for IO-PDT With Porfimer Sodium in Pleural Malignancies
NCT03678350Phase 1Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Sep 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of porfimer sodium in malignant mesothelioma, non-small cell lung cancer (NSCLC) and Pleural disease, sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Incidence of adverse events up to 30 days. Started Sep 2021; status: completed.
02
Drugs
porfimer sodium
03
Conditions
malignant mesotheliomanon-small cell lung cancer (NSCLC)Pleural disease
Beyond the preview
Go deeper on NCT03678350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03678350.